- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Pfizer, BioNTech begin German part of COVID vaccine study
Germany's vaccines regulator, the Paul Ehrlich Institute, gave the approval for the Phase 2/3 trial of the experimental vaccine known as BNT162b2, BioNTech and its partner Pfizer said in a statement.
Frankfurt : Biotech firm BioNTech said on Monday it widened an ongoing pivotal global study of its COVID-19 vaccine candidate to include testing in its home country of Germany.Germany's vaccines regulator, the Paul Ehrlich Institute, gave the approval for the Phase 2/3 trial of the experimental vaccine known as BNT162b2, BioNTech and its partner Pfizer said in a statement.Also Read:...
Frankfurt : Biotech firm BioNTech said on Monday it widened an ongoing pivotal global study of its COVID-19 vaccine candidate to include testing in its home country of Germany.
Germany's vaccines regulator, the Paul Ehrlich Institute, gave the approval for the Phase 2/3 trial of the experimental vaccine known as BNT162b2, BioNTech and its partner Pfizer said in a statement.
Also Read: Bharat Biotech Covid-19 vaccine phase-2 trial to begin in PGI Rohtak
The global trial was initiated in July, with a view to including about 120 sites globally and seeking up to 30,000 participants in total.
More than 25,000 participants have been enrolled,a BioNTech said, adding it remained on track to seek approval for BNT162b2 as early as next month.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.